🇺🇸 FDA
Patent

US 11518816

Methods of delivering an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy

granted A61KA61K2039/505A61K47/6807

Quick answer

US patent 11518816 (Methods of delivering an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy) held by Dyne Therapeutics, Inc. expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K2039/505, A61K47/6807, A61K47/6849, A61K47/6889